Satellos reports positive interim data from adults treated with SAT-3247

CureDuchenne was an early funder of Satellos, and we are pleased to share that they have reported 6-month interim data from 4 individuals (aged 21-28) treated with SAT-3247.  These individuals showed reduced muscle fat fraction, an increase in upper limb effort, increased handgrip strength, and reductions in creatine kinase. 

See press release here:

https://ir.satellos.com/news/news-details/2026/Satellos-Reports-Six-Month-Interim-TRAILHEAD-Data-Showing-Reduced-Muscle-Fat-Fraction-Increased-Effort-Stable-Strength-Lower-CK-and-Favorable-Safety-Profile-in-DMD-Adults-Treated-with-SAT-3247/default.aspx